SCHEMBL14025459

SCHEMBL14025459

CN(Cc1ccccc1)S(=O)(=O)c1ccc(CN(Cc2cnc[nH]2)Cc2ncc[nH]2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
LMNA P02545 3/20 0.42
FNTA P49354 4/20 0.41
CXCR4 P61073 2/20 0.41
FNTB P49356 2/20 0.41
NAMPT P43490 2/20 0.41
TAAR1 Q96RJ0 1/20 0.41
CYP2D6 P10635 1/20 0.41
TSHR P16473 1/20 0.41
PGGT1B P53609 2/20 0.41
CYP3A4 P08684 1/20 0.41
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
GLA P06280 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
ADRB2 P07550 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14025455 0.90 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ALMNACXCR4
SCHEMBL14025460 0.87 NAMPT (0.52) ALDH1A1MEN1KMT2ALMNACXCR4
SCHEMBL14025461 0.83 CXCR3 (0.47) ALDH1A1MEN1KMT2ALMNACXCR4
SCHEMBL14025513 0.81 HTR2B (0.41) FNTACXCR4FNTBNAMPTPGGT1B
SCHEMBL14025624 0.81 CYP2D6 (0.46) ALDH1A1MEN1KMT2ALMNATAAR1
SCHEMBL14045763 0.80 TAAR1 (0.42) LMNAFNTAFNTBTAAR1CYP2D6
SCHEMBL14025629 0.79 PDE4A (0.46) ALDH1A1MEN1KMT2ALMNANAMPT
SCHEMBL4921625 0.77 NAMPT (0.49) ALDH1A1MEN1KMT2ALMNACXCR4
SCHEMBL14025622 0.75 PDE4A (0.46) ALDH1A1MEN1KMT2ALMNATAAR1
SCHEMBL4921630 0.74 ALDH1A1 (0.52) ALDH1A1MEN1KMT2ALMNACXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed
WO-2008109154-A1 CHEMOKINE RECEPTOR MODULATORS ALTIRIS THERAPEUTICS, INC. (US) 2008-09-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A ALDH1A1 423/4885MEN1 173/4885KMT2A 682/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.